Last reviewed · How we verify
Low Dose Quillivant XR
Quillivant XR is an extended-release formulation of methylphenidate that increases dopamine and norepinephrine activity in the central nervous system to improve attention and reduce hyperactivity.
Quillivant XR is an extended-release formulation of methylphenidate that increases dopamine and norepinephrine activity in the central nervous system to improve attention and reduce hyperactivity. Used for Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents.
At a glance
| Generic name | Low Dose Quillivant XR |
|---|---|
| Also known as | Methylphenidate HCl |
| Sponsor | Seattle Children's Hospital |
| Drug class | Central nervous system stimulant; amphetamine-class psychostimulant |
| Target | Dopamine transporter (DAT); norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
Methylphenidate is a central nervous system stimulant that works by blocking the reuptake of dopamine and norepinephrine at the presynaptic neuron, thereby increasing their concentration in the synaptic cleft. The extended-release formulation provides sustained drug delivery over 12 hours, allowing for once-daily dosing. This mechanism enhances executive function, attention span, and impulse control in patients with ADHD.
Approved indications
- Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents
Common side effects
- Decreased appetite
- Insomnia or sleep disturbance
- Headache
- Abdominal pain
- Nervousness or anxiety
- Tachycardia
- Elevated blood pressure
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low Dose Quillivant XR CI brief — competitive landscape report
- Low Dose Quillivant XR updates RSS · CI watch RSS
- Seattle Children's Hospital portfolio CI